美国Plexxikon
Plexxikon公司是结构导向发现领域和治疗人类疾病的新型小分子药品开发领域的领导者。该公司的先导化合物PLX4032用于治疗黑色素瘤，正在进行后期临床试验。该公司正在开发的临床期和临床前期化合物阵容致力于满足心脏-肾脏疾病、中枢神经系统障碍、自身免疫性和神经炎性疾病以及肿瘤领域未获满足的医疗需求。Plexxikon公司专利拥有的Scaffold-Based Drug Discovery™ 平台整合了多种一流技术，包括结构筛选，该关键部件相对于其他药物发现方法具有显著的竞争优势

Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of competitively differentiated clinical and preclinical stage programs in a number of therapeutic areas, including cardio-renal disease, CNS, inflammation, metabolic disease and oncology. Plexxikon’s most advanced program, PLX4032, is currently in pivotal, late-stage clinical trials for the treatment of melanoma. With an option to co-promote PLX4032 in the U.S. as well as a pipeline of oncology opportunities, Plexxikon is laying the foundation for its first commercial franchise—in oncology. Other clinical stage programs include drug candidates for metastatic cancer, polycystic kidney disease, diabetes and rheumatoid arthritis. Plexxikon is uniquely positioned to develop multiple commercial franchises for different therapeutic indications, and build significant value for Plexxikon, its collaborators and investors.

Plexxikon's unique discovery approach, combined with an experienced management and scientific team, a broad network of scientific and clinical experts, and partnership deals that secure near term funding and retain significant commercial rights, have been key drivers of the company's success since it began operations in 2001.

With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process in conjunction with a highly specialized scaffold-like screening library, to design new drug candidates within various families of drug targets. This systematic, cost-efficient approach allows Plexxikon to leverage its target-specific chemistry investment for multiple targets within a given family. Additionally, Plexxikon’s platform has proven particularly amenable to the design of highly selective kinase inhibitors. This selectivity has enhanced the safety profile of its targeted drugs.